Drug Landscape ›
SEVELAMER ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 2,618
Most-reported reactions
Diarrhoea — 318 reports (12.15%) Renal Failure — 290 reports (11.08%) Death — 287 reports (10.96%) Nausea — 286 reports (10.92%) Constipation — 246 reports (9.4%) End Stage Renal Disease — 245 reports (9.36%) Dyspnoea — 243 reports (9.28%) Off Label Use — 243 reports (9.28%) Chronic Kidney Disease — 237 reports (9.05%) Vomiting — 223 reports (8.52%)
Source database →
SEVELAMER in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is SEVELAMER approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for SEVELAMER in United States?
Marketing authorisation holder not available in our data.